Tesamorelin vs Ipamorelin: Two Halves of a Signal

The Short Answer

If you are choosing between these two as substitutes, the honest response is that the question has a flaw in it. A growth hormone pulse runs on two accelerator pedals. Tesamorelin presses one of them, the GHRH receptor. Ipamorelin presses the other, the ghrelin receptor. Asking which is better is a bit like asking whether a car needs the ignition or the fuel pump. In practice they are usually prescribed together, in one vial, for exactly that reason.

If you force a ranking anyway, the evidence does it for you. Tesamorelin has randomized trials in more than 800 people with the outcome measured on a CT scanner, and an FDA approval behind it. Ipamorelin has one dosing study in 40 healthy men, a Phase 2 program that missed its endpoint, and no study of any kind that measured body fat, muscle, sleep, or recovery. That gap is the most useful thing on this page, and it is the thing most comparison articles leave out.

Tesamorelin vs Ipamorelin at a Glance

Two rows deserve a second look. Ipamorelin has never been given under the skin in a published human study, which is the only way anyone prescribes it, and nobody has measured what it does to fat or muscle in a person. Neither fact makes ipamorelin useless. Both make the neat comparison tables online less informative than they look.

Two Accelerators, Not Two Rivals

Your pituitary releases growth hormone in bursts, and the size of each burst is set by three inputs. Growth hormone-releasing hormone, GHRH, arrives from the hypothalamus and drives both production and release. A second signal works through the ghrelin receptor and amplifies the release itself. Somatostatin is the brake that closes each pulse off. Tesamorelin and ipamorelin each target one of the two accelerators, and neither touches the brake.

Tesamorelin is native GHRH with armor. The natural hormone is 44 amino acids long and an enzyme called DPP-IV clips it within minutes. Theratechnologies attached a hexenoyl group to the first amino acid, which blocks that cut while leaving the full chain and its receptor binding intact. The result behaves like a longer, sturdier version of the body's own instruction. In the pivotal trial it raised IGF-1 by 81 percent over 26 weeks.

Ipamorelin came from the opposite direction. Novo Nordisk chemists started from an older compound, GHRP-1, and stripped out its central pair of amino acids. What remained was a pentapeptide that released growth hormone about as powerfully as the reference compound of the day, and did it through the ghrelin receptor rather than the GHRH receptor.

Raun K, Hansen BS, Johansen NL, et al. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology. 1998;139(5):552-61. Cell, rat, and conscious swine data. View study

Because the two pathways are separate, working both at once produces more growth hormone than working either alone. That principle was demonstrated in healthy men in 1990, with a caveat worth stating plainly: the ghrelin-pathway peptide in that study was GHRP-6, an older cousin, not ipamorelin. No published human study has tested ipamorelin alongside a GHRH analog. The pairing rests on shared mechanism and clinical experience rather than on a trial of the combination itself.

Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. "Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone." Journal of Clinical Endocrinology and Metabolism. 1990;70(4):975-82. Study of GHRP-6, not ipamorelin. View study

The Evidence Asymmetry

This is the section other comparison pages skip, and it is the one that should decide most of your thinking. Put the two literatures side by side and one column is full while the other is close to empty.

What tesamorelin has

Tesamorelin is the unusual case of a compounded peptide whose results question has a published answer. In the pivotal trial, 412 patients with HIV and abdominal fat accumulation, 86 percent of them men, injected 2 mg or placebo daily for 26 weeks. Visceral fat on CT fell 15.2 percent on tesamorelin and rose 5.0 percent on placebo. Triglycerides dropped 50 mg/dL while the placebo group rose 9. A second Phase 3 trial in 404 patients found a 10.9 percent reduction against 0.6 percent, reaching roughly 18 percent in patients who stayed on it for twelve months. In the authors' own words, those gains were rapidly lost in people switched to placebo.

Falutz J, Allas S, Blot K, et al. "Metabolic effects of a growth hormone-releasing factor in patients with HIV." New England Journal of Medicine. 2007;357(23):2359-70. View study

Falutz J, Potvin D, Mamputu JC, et al. "Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension." Journal of Acquired Immune Deficiency Syndromes. 2010;53(3):311-22. View study

One randomized trial tested the molecule outside HIV. Sixty abdominally obese adults with reduced growth hormone secretion took 2 mg daily or placebo for twelve months. Visceral fat fell by 35 square centimeters relative to placebo, the fat under the skin did not change, and fasting glucose, two-hour glucose, and HbA1c all held steady. Sixty people is not 816, but it points the same direction outside the original population.

Makimura H, Feldpausch MN, Rope AM, et al. "Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial." Journal of Clinical Endocrinology and Metabolism. 2012;97(12):4769-79. View study

What ipamorelin has

The entire published human record for ipamorelin is two studies. The first was a dosing study run by Novo Nordisk with the University at Buffalo. Forty healthy men, eight at each of five dose levels, received a 15-minute intravenous infusion. Ipamorelin behaved predictably: blood levels tracked the dose, the terminal half-life came out around two hours, and growth hormone appeared as one episode peaking about forty minutes in before falling away. That study answered how the molecule moves and how the pituitary answers it. It measured nothing else.

Gobburu JV, Agersø H, Jusko WJ, Ynddal L. "Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers." Pharmaceutical Research. 1999;16(9):1412-6. Healthy men, intravenous infusion. View study

The second was a trial for something else entirely. Ghrelin-receptor drugs speed up the gut, and after bowel surgery the gut often stalls for days. Helsinn Therapeutics tested ipamorelin in 117 adults having bowel resections, given intravenously at 0.03 mg per kilogram twice daily for up to a week. Patients on ipamorelin tolerated a solid meal at a median of 25.3 hours against 32.6 on placebo, a gap that did not reach statistical significance, and no secondary measure separated the groups either. The authors called it well tolerated and concluded it did not work.

Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. "Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients." International Journal of Colorectal Disease. 2014;29(12):1527-34. View study

In fairness to ipamorelin, tesamorelin has not had sleep or recovery measured either. Its trials looked at abdominal fat, lipids, and IGF-1. If sleep is your goal, neither peptide can point you at a result. The difference is that tesamorelin has a measured outcome somewhere and ipamorelin has none.

Which Question Are You Actually Asking?

Most people arriving at this comparison are asking one of three different questions wearing the same words. Sorting out which one you have makes the answer straightforward.

"I want my waist to shrink while the scale holds steady." That is tesamorelin's lane and the only one of the three with trial evidence behind it. The compartment that moved in those studies was visceral fat, the deep kind behind the muscle wall, while the pinchable layer under the skin was untouched. A realistic result is a smaller waist and better triglycerides, measured over months rather than weeks. Tesamorelin results Read nextTesamorelin Results: What the Trials Actually ShowedSearch for results on almost any peptide and you get mouse studies and marketing. Tesamorelin is the exception. The molecule went through two Phase 3 randomized trials with more than 800 patients, and the endpoint was not a survey or a scale. It was visceral fat measured by CT scan. This article walks through those numbers, the population they came from, what a realistic timeline looks like, and why the honest version of "tesamorelin before and after" involves a tape measure instead of a mirror.Read article walks through the full numbers and timeline.

"I want a bigger growth hormone response overall." Then the answer is not one or the other, it is both. Two accelerators produce a larger pulse than one, which is the entire rationale for the blended vial. What you should know going in is that the blend itself has never been tested in a trial, even though each component has been characterized separately. Tesamorelin/Ipamorelin Read nextTesamorelin/Ipamorelin: Dosage and Cost (2026)Tesamorelin is the only FDA-approved GHRH analog, and the only GH peptide with Phase 3 trial data on visceral fat. This guide pairs it with Ipamorelin and focuses on what tesamorelin is actually proven to do: shrink deep abdominal fat, lower liver fat, and drive metabolic recomposition. If you want a general GH-support stack, the CJC-1295/Ipamorelin guide covers that. This page is about the FDA-approved, visceral-fat side of the GH peptide world.Read article covers the combination in full.

"I want to lose weight." Neither. The Egrifta label states that tesamorelin is not indicated for weight loss management because its effect on body weight is neutral, and no ipamorelin study has measured weight in people at all. Do peptides help you lose weight Read nextDo Peptides Help You Lose Weight? An Honest AnswerSome peptides genuinely help people lose weight. Most of the ones sold online do not. The line between the two is not marketing, it is drug class, and you can learn where it sits in about ten minutes. This page gives the verdict first and the reasoning after.Read article is the more useful starting point.

EGRIFTA SV (tesamorelin for injection) prescribing information. Theratechnologies Inc. Revised July 2019. Section 1 limitations of use: "not indicated for weight loss management as it has a weight neutral effect." Section 5.4 covers glucose intolerance and the instruction to evaluate glucose before and during therapy. View study

Safety splits less cleanly than the evidence does. Both raise IGF-1, so active cancer rules out either, a cancer history gets weighed carefully, and neither is used in pregnancy or breastfeeding. Tesamorelin has the better-documented list thanks to its FDA label, glucose warning included. Ipamorelin's risk picture is thinner in both directions: FDA reviewers found no published genotoxicity, reproductive, or carcinogenicity studies for it. Lab work before starting peptides Read nextLab Work Before Starting PeptidesThe honest answer to "what bloodwork do I need before peptides?" is: it depends on the peptide, and for many of them the answer is none. Some sites will tell you to buy a full baseline panel before anything, because they sell the panel. Here is the real picture, which peptides typically need no labs, where a provider may want to check IGF-1 and a metabolic panel, and why the decision belongs to the provider reviewing your history rather than to a checklist.Read article covers what is worth having on file first.

FDA Status: The Second Asymmetry

US Food and Drug Administration. Final summary minutes, Pharmacy Compounding Advisory Committee meeting, October 29, 2024. Vote results for ipamorelin (free base) and ipamorelin acetate. View study

We would rather state that plainly than let it sit in a footnote, because it is a real difference between the two halves of the vial. Our ipamorelin guide Read nextIpamorelin Peptide: What It Does, Doses, EvidenceIpamorelin is a five-amino-acid peptide that tells the pituitary to release a pulse of growth hormone. Its reputation rests on one word, selective, and that word traces back to a 1998 experiment in pigs. The human record is narrower than most pages admit: one dosing study by IV infusion and a surgical program that failed. This guide covers what ipamorelin does, where the dose numbers online come from, what FDA reviewers concluded in 2024, and why we only prescribe it paired.Read article goes through what FDA reviewers found in detail, and CJC-1295 Read nextCJC-1295 Peptide: What It Is, DAC vs No DACCJC-1295 is a lab-made version of the hormone that tells your pituitary to release growth hormone. The complication is that two different molecules are sold under that one name, one built to last a week and one built to clear quickly, and almost every published human result belongs to only one of them. This guide sorts out which is which, what the evidence covers, and why we had to pick a side.Read article went through a near-identical process five weeks later.

Anti-doping treats them as siblings rather than opposites, which is a useful tell about how they are classified. The 2026 World Anti-Doping Agency Prohibited List puts both in section S2.2.4, growth hormone releasing factors. Tesamorelin sits on the bullet for GHRH analogues alongside sermorelin Explore PeRxSermorelinThe Growth Hormone OptimizerView peptide and CJC-1295. Ipamorelin sits on the next bullet, growth hormone secretagogues, alongside ibutamoren and ghrelin itself. Both are prohibited at all times, in and out of competition, and a prescription does not change that. Peptide therapy for athletes Read nextPeptide Therapy for Athletes: WADA Rules & UseAthletes were among the earliest adopters of peptide therapy, and for good reason. Faster recovery between training sessions, accelerated injury repair, and improved body composition are directly relevant to athletic performance. But there are rules, and understanding the competitive landscape matters as much as the pharmacology.Read article covers the wider picture.

Why There Is No Standalone Ipamorelin Vial

If you planned to buy ipamorelin by itself and test it against tesamorelin in your own body, that option does not exist here. We prescribe ipamorelin only inside a blend, for the reason at the top of this page. A ghrelin-receptor agonist triggers release, but how much growth hormone is there to release depends on the GHRH signal. One pedal gives you a pulse. Both give you a larger one.

That leaves two practical options and a clear price difference. Tesamorelin Explore PeRxTesamorelinMetabolic Optimization PeptideView peptide on its own is $229 for a one-month vial at 3 mg/mL. Tesamorelin/Ipamorelin Explore PeRxTesamorelin/IpamorelinVisceral Fat & Lean Muscle GH ComboView peptide is $299 for a single 5 mL vial holding tesamorelin at 3 mg/mL and ipamorelin at 2 mg/mL, drawn as one injection so a single draw sets both doses. Seventy dollars is what the second pathway costs. Either price covers the provider review, compounding at a US 503A pharmacy, refrigerated overnight shipping, syringes, and swabs. Checkout saves your card and the charge runs only if a provider approves the prescription.

The other GHRH half on offer is CJC-1295, in the CJC-1295/Ipamorelin Read nextCJC-1295 Ipamorelin: The Complete GuideCJC-1295 Ipamorelin pairs a GHRH signal that primes growth hormone release with a clean pulse trigger that fires it. After age 30, your body produces roughly 15% less growth hormone every decade. This stack doesn't replace what you've lost with synthetic hormones. It tells your body to start making more of its own again. Together, the two peptides form the most popular growth hormone optimization protocol in peptide therapy.Read article blend at the same $299, a swap that trades tesamorelin's trial record for a more general-purpose analog. The neighbouring decisions have their own pages: sermorelin vs ipamorelin vs tesamorelin Read nextSermorelin vs Ipamorelin vs Tesamorelin: Which Fits?All three raise your own growth hormone, but they pull different levers, last for different amounts of time, and suit different goals. This is a decision guide, not a spec sheet: match the peptide to what you actually want.Read article , tesamorelin vs sermorelin Read nextTesamorelin vs Sermorelin: Which One Fits Your Goal?Tesamorelin and sermorelin press the same button on the pituitary, so most comparison pages end up ranking them by strength. That misses the point. One has two Phase 3 trials with CT scans behind a single, narrow result. The other has more than three decades of clinical history and a thin adult evidence file. PeRx prescribes both at the same price, which leaves the only question that matters: what are you actually trying to change?Read article , and tesamorelin vs CJC-1295 Read nextTesamorelin vs CJC-1295/Ipamorelin 2026: FDA vs DualTesamorelin is the only FDA-approved growth hormone peptide. CJC-1295/Ipamorelin is the most popular compounded GH stack. Both stimulate your pituitary to produce growth hormone, but they do it differently and they have very different regulatory histories. Here is the honest comparison to help you choose.Read article .

Common Questions

Liu H, Bravata DM, Olkin I, et al. "Systematic review: the safety and efficacy of growth hormone in the healthy elderly." Annals of Internal Medicine. 2007;146(2):104-15. Injected growth hormone, not a peptide secretagogue. View study